Previous entity Next entity
logo GRAALL

GRAALL

The GRAALL aims to develop scientific knowledge on Leukemias Acute Lymphoblastic Diseases (ALL) of adults and their treatment in order to improve the survival of patients.

Image GRAALL
Nicolas Boissel
Prof. Nicolas Boissel

Head of Entity

Contact

Email : nicolas.boissel@aphp.fr

Association GRAALL
Centre Hospitalier Lyon-Sud,
Service d'Hématologie Marcel Bérard - Secteur 1G
69495 PIERRE-BÉNITE - France

  • Acute Lymphoblastic Leukemia (ALL)

  • To improve the understanding of oncogenesis mechanisms in Acute Lymphoblastic Leukemia (ALL)
  • To evaluate new therapeutic approaches including immunotherapy and targeted therapies in the field of acute lymphoblastic leukemia
  • To identify and validate new biomarkers predictive of response to conventional and new therapies 
  • To evaluate the long-term health status of patients treated with intensive chemotherapy approaches

 

  • Targeted therapy
  • Immunotherapy

Scientific

Minimal residual disease

  • Validation of MRD as prognostic factor
  • Validation of MRD as sole indication of alloHSCT in Ph- ALL
  • Refinement of MRD strategy in specific subgroups

Incorporation of new biomarkers

  • IKZF1 in Ph- B-ALL
  • NOTCH1/FBXW7/RAS/PTEN classifier in T-ALL

Discovery of new entities and therapeutics pathways 

  • B-ALL : Ph-like and TKI, PAX5P80R, UBTF::ATXN7L3, TP53
  • T-ALL : ETP, DNMT3A, PRC2, IKZF1, IL7R

Medical

Ph-negative ALL

  • Benefit and feasibility of “Pediatric-like” intensive approach 
  • Safety of decreased indications of alloHSCT based on MRD
  • Benefit of Rituximab in CD20+ B-ALL
  • Benefit of Blinatumomab in HR B-ALL
  • Nelarabine in HR T-ALL

Ph-positive ALL

  • Feasibility chemotherapy de-escalation with  Imatinib
  • Limits of chemotherapy de-escalation with Nilotinib

  • Benefit of a pediatric-inspired chemotherapy approach in adults aged up to 60 years with Philadelphia-negative ALL (GRAALL-2003 : Huguet F, et al. J Clin Oncol 2009;27:911–8)
  • Predominant prognostic impact of minimal residual disease (MRD) and oncogenetics in adult Philadelphia-negative ALL (GRAALL-2005 : Beldjord K, et al. Blood. 2014;123(24):3739-3749)
  • Predictive value of minimal residual disease in the benefit of allogeneic stem cell transplant in Philadelphia-negative ALL (GRAALL-2005 : Dhédin N, et al. Blood 2015;125:2486–96)
  • Benefit of rituximab in CD20-positive Philadelphia-negative adult ALL (Phase 3 R-GRAALL-2005 : Maury S et al., N Engl J Med. 2016 Sep 15;375(11):1044-53)
  • Feasibility of chemotherapy de-escalation in adults with Philadelphia-positive ALL (Phase 3 GRAAPH-2005 : Chalandon Y, et al. Blood 2015;125:3711-3719).

Research infrastructures

MRD

MRD (Minimal Residual Disease) platforms - 5 locations: 

  • CHRU Lille, Laboratory of Prof. Claude Preudhomme
  • Necker Hospital, Laboratory of Prof. Vahid Asnafi
  • Saint Louis Hospital, Laboratory of Prof. Jean Soulier
  • CHU Rennes, Laboratory of Prof. Thierry Fest
  • Toulouse University Cancer Institute Oncopole, Laboratory of Prof. Eric Delabesse
  • Zürich University Hospital, Prof. Beat Schaefer
  • Universitair Ziekenhuis Brussel, Dr. Marleen Bakkus

 

Data center

 

Data Processing Center (CTD) and Biostatistics and Medical Information Department (SBIM) (Dr. Jérôme Lambert, Prof. Sylvie Chevret), Hôpital Saint-Louis, Paris.

 

Oncogenetics

Oncogenetics laboratories – 2 locations: 

  • Necker Hospital, Laboratory of Prof. Vahid Asnafi – specification: T-ALL/T-LL
  • Hôpital Saint-Louis, Laboratoire du Prof. Emmanuelle Clappier – specification: B-ALL/B-LL

 

 

 

 

 

 

Biological samples

 

Clinical trial

ALL

“GRAALL-Thèque ALL-B “: Saint-Louis Hospital, Laboratory of Prof. Emmanuelle Clappier.

“GRAALL-Thèque ALL-T “: Necker Hospital, Laboratory of Prof. Vahid Asnafi.

 

Cohort

Clinical data

Real life cohort – “CAR-T cells (DESCAR-T, National registry for patients with hem malignancies treated with CAR-T)”.

 

Real life cohort – “Blinatumomab (ATU)”.

 

Real life cohort – “Relapses: T-ALL, Ph-positive ALL”

 

Partnership research offers

NATIONAL CLINICAL RESEARCH NETWORK FOR THE DESIGN, SPONSORING AND CONDUCT OF PHASE II TO IV INTERVENTIONAL AND NON-INTERVENTIONAL CLINICAL TRIALS (ALL)

Partners

Academics

Affiliation

Group for Research on Adult Acute Lymphoblastic Leukemia (GRAALL)